Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 6/2016

01-06-2016 | Invited article

Imaging patients with renal impairment

Authors: Mahan Mathur, Jeffrey C. Weinreb

Published in: Abdominal Radiology | Issue 6/2016

Login to get access

Abstract

Imaging with intravascular contrast media is generally considered safe, particularly in patients without renal failure. However, as renal function deteriorates, the potential risk of nonallergic-type adverse events increases. This presents a unique challenge, particularly when the use of intravenous contrast media is deemed essential for diagnostic purposes. Following a discussion regarding the definition and epidemiology of kidney injury, this review focuses on the evolving understanding of both contrast-induced nephropathy and nephrogenic systemic fibrosis and discusses preventative strategies aimed at minimizing the risk of developing these entities. Alternative non-contrast imaging techniques are also discussed.
Literature
1.
2.
American College of Radiology (2015) Committee on drugs and contrast media. ACR manual on contrast media version 10.1
3.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204PubMedPubMedCentralCrossRef
4.
Mehta RL, Kellum JA, Shah SV, et al. (2007) Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31PubMedPubMedCentralCrossRef
5.
Davenport MS, Khalatbari S, Cohan RH, et al. (2013) Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 268(3):719–728. doi:10.​1148/​radiol.​13122276 PubMedCrossRef
6.
7.
McDonald RJ, McDonald JS, Carter RE, et al. (2014) Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology 273(3):714–725PubMedCrossRef
8.
Eknoyan G, Levin N (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification-foreword. Am J Kidney Dis 39(2):S14–S266CrossRef
9.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl 1–150
10.
Levey AS, de Jong PE, Coresh J, et al. (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 80(1):17–28PubMedCrossRef
11.
Stevens LA, Levey AS (2009) Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 20(11):2305–2313PubMedCrossRef
12.
Stevens LA, Schmid CH, Greene T, et al. (2010) Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 56(3):486–495PubMedPubMedCentralCrossRef
13.
Levey AS, Bosch JP, Lewis JB, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130(6):461–470PubMedCrossRef
14.
Levey AS, Eckardt K-U, Tsukamoto Y, et al. (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67(6):2089–2398PubMedCrossRef
15.
Levin A, Stevens PE (2014) Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85(1):49–61PubMedCrossRef
16.
Davenport MS, Khalatbari S, Cohan RH, Ellis JH (2013) Contrast medium–induced nephrotoxicity risk assessment in adult inpatients: a comparison of serum creatinine level–and estimated glomerular filtration rate–based screening methods. Radiology 269(1):92–100PubMedPubMedCentralCrossRef
17.
Rydahl C, Thomsen HS, Marckmann P (2008) High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43(2):141–144PubMedCrossRef
18.
Thomsen H, Bellin M-F, Jakobsen J, Webb JW (2014) Contrast media classification and terminology. In: Thomsen HS, Webb JAW (eds). Contrast media. Medical radiology. Berlin: Springer, pp 3–11. doi:10.​1007/​174_​2013_​864
19.
Morcos S, Thomsen H (2001) Adverse reactions to iodinated contrast media. Eur Radiol 11(7):1267–1275PubMedCrossRef
20.
21.
Davenport MS, Cohan RH, Ellis JH (2015) Contrast media controversies in 2015: imaging patients with renal impairment or risk of contrast reaction. Am J Roentgenol 204(6):1174–1181. doi:10.​2214/​AJR.​14.​14259 CrossRef
22.
Katzberg RW, Lamba R (2009) Contrast-induced nephropathy after intravenous administration: fact or fiction? Radiol Clin North Am 47(5):789–800PubMedCrossRef
23.
Bartels ED, Brun G, Gammeltoft A, GjØrup PA (1954) Acute Annria following intravenous pyelography in a patient with myelomatosis. Acta Medica Scand 150(4):297–302CrossRef
24.
Murphy SW, Barrett BJ, Parfrey PS (2000) Contrast nephropathy. J Am Soc Nephrol 11(1):177–182PubMed
25.
Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT (1983) Hospital-acquired renal insufficiency: a prospective study. Am J Med 74(2):243–248PubMedCrossRef
26.
Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39(5):930–936PubMedCrossRef
27.
Rao QA, Newhouse JH (2006) Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis 1. Radiology 239(2):392–397PubMedCrossRef
28.
Moore R, Steinberg E, Powe N, et al. (1992) Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 182(3):649–655PubMedCrossRef
29.
Lufft V, Hoogestraat-Lufft L, Fels LM, et al. (2002) Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis 40(2):236–242PubMedCrossRef
30.
Cramer BC, Parfrey PS, Hutchinson TA, et al. (1985) Renal function following infusion of radiologic contrast material: a prospective controlled study. Arch Intern Med 145(1):87–89PubMedCrossRef
31.
Heller C, Knapp J, Halliday J, O’Connell D, Heller R (1991) Failure to demonstrate contrast nephrotoxicity. Med J Australia 155(5):329–332PubMed
32.
Newhouse JH, Kho D, Rao QA, Starren J (2008) Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. Am J Roentgenol 191(2):376–382. doi:10.​2214/​AJR.​07.​3280 CrossRef
33.
Moore A, Dickerson E, Dillman JR, et al. (2014) Incidence of nonconfounded post-computed tomography acute kidney injury in hospitalized patients with stable renal function receiving intravenous iodinated contrast material. Curr Probl Diagn Radiol 43(5):237–241PubMedCrossRef
34.
McDonald JS, McDonald RJ, Comin J, et al. (2013) Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 267(1):119–128PubMedCrossRef
35.
Davenport MS, Cohan RH, Khalatbari S, Ellis JH (2014) The challenges in assessing contrast-induced nephropathy: where are we now? Am J Roentgenol 202(4):784–789CrossRef
36.
McDonald JS, McDonald RJ, Carter RE, et al. (2014) Risk of intravenous contrast material–mediated acute kidney injury: a propensity score–matched study stratified by baseline-estimated glomerular filtration rate. Radiology 271(1):65–73PubMedCrossRef
37.
McDonald RJ, McDonald JS, Bida JP, et al. (2013) Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 267(1):106–118PubMedCrossRef
38.
McDonald RJ, McDonald JS, Newhouse JH, Davenport MS (2015) Controversies in contrast material-induced acute kidney injury: closing in on the truth? Radiology 277(3):627–632PubMedCrossRef
39.
McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103(5):368–375PubMedCrossRef
40.
Nikolsky E, Mehran R, Turcot D, et al. (2004) Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 94(3):300–305PubMedCrossRef
41.
Chao C (2013) Epidemiology, clinical features and diagnosis of contrast induced nephropathy: a brief review. Gen Med 1(102):2
42.
Rihal CS, Textor SC, Grill DE, et al. (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105(19):2259–2264PubMedCrossRef
43.
Dashti-Khavidaki S, Moghaddas A, Heydari B, Khalili H, Lessan-Pezeshki M (2013) Statins against drug-induced nephrotoxicity. J Pharm Pharm Sci 16(4):588–608PubMed
44.
Goergen SK, Rumbold G, Compton G, Harris C (2009) Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin 1. Radiology 254(1):261–269CrossRef
45.
Elicker BM, Cypel YS, Weinreb JC (2006) IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. Am J Roentgenol 186(6):1651–1658CrossRef
46.
Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME (2008) Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels 1. Radiology 248(1):106–113PubMedCrossRef
47.
Kooiman J, Seth M, Share D, Dixon S, Gurm HS (2014) The association between contrast dose and renal complications post PCI across the continuum of procedural estimated risk. PloS One 9(3):e90233.
48.
Trivedi H, Foley WD (2010) Contrast-induced nephropathy after a second contrast exposure. Ren Fail 32(7):796–801PubMedCrossRef
49.
Balemans CE, Reichert LJ, van Schelven BI, van den Brand JA, Wetzels JF (2012) Epidemiology of contrast material–induced nephropathy in the era of hydration. Radiology 263(3):706–713PubMedCrossRef
50.
Barrett B, Carlisle E (1993) Metaanalysis of the relative nephrotoxicity of high-and low-osmolality iodinated contrast media. Radiology 188(1):171–178PubMedCrossRef
51.
McCullough PA, Bertrand ME, Brinker JA, Stacul F (2006) A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 48(4):692–699PubMedCrossRef
52.
Feldkamp T, Baumgart D, Elsner M, et al. (2006) Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol 66(5):322–330PubMedCrossRef
53.
Heinrich MC, Häberle L, Müller V, Bautz W, Uder M (2009) Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials 1. Radiology 250(1):68–86PubMedCrossRef
54.
Au TH, Bruckner A, Mohiuddin SM, Hilleman DE (2014) The prevention of contrast-induced nephropathy. Ann Pharmacother 48(10):1332–1342PubMedCrossRef
55.
Ellis JH, Cohan RH (2009) Reducing the risk of contrast-induced nephropathy: a perspective on the controversies. Am J Roentgenol 192(6):1544–1549CrossRef
56.
Jakobsen J, Berg K, Waaler A, Andrew E (1990) Renal effects of the non-ionic contrast medium iopentol after intravenous injection in healthy volunteers. Acta Radiol 31(1):87–91PubMedCrossRef
57.
Ellis JH, Cohan RH (2009) Prevention of contrast-induced nephropathy: an overview. Radiol Clin North Am 47(5):801–811PubMedCrossRef
58.
Thomsen HS (2007) Current evidence on prevention and management of contrast-induced nephropathy. Eur Radiol Suppl 17(6):33–37CrossRef
59.
Hiremath S, Akbari A, Shabana W, Fergusson DA, Knoll GA (2013) Prevention of contrast-induced acute kidney injury: is simple oral hydration similar to intravenous? A systematic review of the evidence. PLoS ONE 8(3):e60009PubMedPubMedCentralCrossRef
60.
Mueller C, Buerkle G, Buettner HJ, et al. (2002) Prevention of contrast media–associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162(3):329–336PubMedCrossRef
61.
Merten GJ, Burgess WP, Gray LV, et al. (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291(19):2328–2334PubMedCrossRef
62.
Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR (2009) Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 53(4):617–627PubMedCrossRef
63.
Zoungas S, Ninomiya T, Huxley R, et al. (2009) Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 151(9):631–638PubMedCrossRef
64.
Dussol B, Morange S, Loundoun A, Auquier P, Berland Y (2006) A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 21(8):2120–2126PubMedCrossRef
65.
Tepel M, Van Der Giet M, Schwarzfeld C, et al. (2000) Prevention of radiographic-contrast-agent–induced reductions in renal function by acetylcysteine. N Engl J Med 343(3):180–184PubMedCrossRef
66.
Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008) Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148(4):284–294PubMedCrossRef
67.
Stenstrom DA, Muldoon LL, Armijo-Medina H, et al. (2008) N-acetylcysteine use to prevent contrast medium–induced nephropathy: premature phase III trials. J Vasc Interv Radiol 19(3):309–318PubMedCrossRef
68.
Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK (2004) The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15(2):407–410PubMedCrossRef
69.
Bagshaw SM, Ghali WA (2005) Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 165(10):1087–1093PubMedCrossRef
70.
Ix JH, McCulloch CE, Chertow GM (2004) Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transpl 19(11):2747–2753CrossRef
71.
Solomon R, Werner C, Mann D, D’Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331(21):1416–1420PubMedCrossRef
72.
Singh N, Lee JZ, Huang JJ, et al. (2014) Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart 1(1):e000127PubMedPubMedCentralCrossRef
73.
Bonetti P, Lerman L, Napoli C, Lerman A (2003) Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J 24(3):225–248PubMedCrossRef
74.
Goldenberg I, Matetzky S (2005) Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. Can Med Assoc J 172(11):1461–1471CrossRef
75.
Cruz DN, Perazella MA, Bellomo R, et al. (2006) Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 48(3):361–371PubMedCrossRef
76.
Lehnert T, Keller E, Gondolf K, et al. (1998) Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transpl 13(2):358–362CrossRef
77.
Marenzi G, Marana I, Lauri G, et al. (2003) The prevention of radiocontrast-agent–induced nephropathy by hemofiltration. N Engl J Med 349(14):1333–1340PubMedCrossRef
78.
Sterling KA, Tehrani T, Rudnick MR (2008) Clinical significance and preventive strategies for contrast-induced nephropathy. Curr Opin Nephrol Hypertens 17(6):616–623PubMedCrossRef
79.
Morcos S, Thomsen H, Webb J (2002) Members of contrast media safety committee of the european society of urogenital radiology (ESUR). Dialysis and contrast media. Eur Radiol 12(12):3026–3030PubMed
80.
Cowper SE, Robin HS, Steinberg SM, et al. (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356(9234):1000–1001PubMedCrossRef
81.
Besheli LD, Aran S, Shaqdan K, Kay J, Abujudeh H (2014) Current status of nephrogenic systemic fibrosis. Clin Radiol 69(7):661–668CrossRef
82.
Braverman IM, Cowper S (2010) Nephrogenic systemic fibrosis. F1000 medicine reports 2
83.
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis 1. Radiology 242(3):647–649PubMedCrossRef
84.
Marckmann P, Skov L, Rossen K, Thomsen H (2008) Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 69(3):161–168PubMedCrossRef
85.
Marckmann P, Skov L (2009) Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am 47(5):833–840PubMedCrossRef
86.
Weller A, Barber JL, Olsen ØE (2014) Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 29(10):1927–1937PubMedCrossRef
87.
Thomsen HS, Marckmann P, Logager VB (2008) Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 16(4):551–560PubMedCrossRef
88.
Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transpl 21(4):1104–1108CrossRef
89.
Marckmann P, Skov L, Rossen K, et al. (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17(9):2359–2362PubMedCrossRef
90.
Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66(2):230–234PubMedCrossRef
91.
92.
Thomsen HS (2009) Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 47(5):827–831PubMedCrossRef
93.
94.
Thomsen HS, Webb JAW (2014) Appendix A: ESUR guidelines on contrast media version 8.1. In: Contrast media. Springer, pp 257–274
95.
Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W (2009) Risk factors for NSF: a literature review. J Magn Reson Imaging 30(6):1298–1308PubMedCrossRef
96.
Prince MR, Zhang H, Morris M, et al. (2008) Incidence of nephrogenic systemic fibrosis at two large medical centers 1. Radiology 248(3):807–816PubMedCrossRef
97.
Othersen JB, Maize JC, Woolson RF, Budisavljevic MN (2007) Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transpl 22(11):3179–3185CrossRef
98.
Broome DR, Girguis MS, Baron PW, et al. (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 188(2):586–592CrossRef
99.
Todd DJ, Kagan A, Chibnik LB, Kay J (2007) Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56(10):3433–3441PubMedCrossRef
100.
Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS (2007) Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22(11):3174–3178PubMedCrossRef
101.
Shibui K, Kataoka H, Sato N, et al. (2009) A case of NSF attributable to contrast MRI repeated in a patient with Stage 3 CKD at a renal function of eGFR > 30 mL/min/1.73 m2. Jpn J Nephrol 51:676
102.
Kalb R, Helm T, Sperry H, et al. (2008) Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 158(3):607–610PubMedCrossRef
103.
Abu-Alfa AK (2011) Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis 18(3):188–198PubMedCrossRef
104.
Graziani G, Montanelli A, Brambilla S, Balzarini L (2009) Nephrogenic systemic fibrosis an unsolved riddle. J Nephrol 22(2):203–207PubMed
105.
Zhang B, Liang L, Chen W, Liang C, Zhang S (2015) An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. PLoS ONE 10(6):e0129720PubMedPubMedCentralCrossRef
106.
Reiter T, Ritter O, Prince MR, et al. (2012) Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 14(1):31PubMedPubMedCentralCrossRef
107.
Shaw DR, Kessel DO (2006) The current status of the use of carbon dioxide in diagnostic and interventional angiographic procedures. Cardiovasc Interv Radiol 29(3):323–331CrossRef
108.
Dunn DP, Kelsey NR, Lee KS, Smith MP, Mortele KJ (2015) Non-oncologic applications of diffusion-weighted imaging (DWI) in the genitourinary system. Abdom Imaging 40(6):1645–1654PubMedCrossRef
109.
Kono K, Inoue Y, Nakayama K, et al. (2001) The role of diffusion-weighted imaging in patients with brain tumors. Am J Neuroradiol 22(6):1081–1088PubMed
110.
Zelhof B, Pickles M, Liney G, et al. (2009) Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 103(7):883–888PubMedCrossRef
111.
Bruegel M, Holzapfel K, Gaa J, et al. (2008) Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 18(3):477–485PubMedCrossRef
112.
Sandrasegaran K, Sundaram CP, Ramaswamy R, et al. (2010) Usefulness of diffusion-weighted imaging in the evaluation of renal masses. Am J Roentgenol 194(2):438–445CrossRef
113.
Bruining DH, Bhatnagar G, Rimola J et al (2015) CT and MR enterography in Crohn’s disease: current and future applications. Abdom Imaging 1–10
114.
Chan JHM, Tsui EYK, Luk SH, et al. (2001) MR diffusion-weighted imaging of kidney: differentiation between hydronephrosis and pyonephrosis. Clin Imaging 25(2):110–113PubMedCrossRef
115.
Verswijvel G, Vandecaveye V, Gelin G, et al. (2002) Diffusion-weighted MR imaging in the evaluation of renal infection: preliminary results. Jbr-Btr 85(2):100–103PubMed
116.
Dumoulin CL, Cline HE, Souza SP, Wagle WA, Walker MF (1989) Three-dimensional time-of-flight magnetic resonance angiography using spin saturation. Magn Reson Med 11(1):35–46PubMedCrossRef
117.
Ivancevic MK, Geerts L, Weadock WJ, Chenevert TL (2009) Technical principles of MR angiography methods. Magn Reson Imaging Clin N Am 17(1):1–11PubMedCrossRef
118.
Wilson GJ, Maki JH (2009) Non–contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. Magn Reson Imaging Clin N Am 17(1):13–27PubMedCrossRef
119.
Loubeyre P, Trolliet P, Cahen R, et al. (1996) MR angiography of renal artery stenosis: value of the combination of three-dimensional time-of-flight and three-dimensional phase-contrast MR angiography sequences. AJR Am J Roentgenol 167(2):489–494PubMedCrossRef
120.
Wyttenbach R, Braghetti A, Wyss M, et al. (2007) Renal artery assessment with nonenhanced steady-state free precession versus contrast-enhanced MR angiography 1. Radiology 245(1):186–195PubMedCrossRef
121.
Maki JH, Wilson GJ, Eubank WB, et al. (2007) Steady-state free precession MRA of the renal arteries: breath-hold and navigator-gated techniques vs CE-MRA. J Magn Reson Imaging 26(4):966–973PubMedCrossRef
122.
Maki JH, Wilson GJ, Eubank WB, et al. (2007) Navigator-gated MR angiography of the renal arteries: a potential screening tool for renal artery stenosis. Am J Roentgenol 188(6):W540–W546CrossRef
123.
Herborn CU, Watkins DM, Runge VM, et al. (2006) Renal arteries: comparison of steady-state free precession MR angiography and contrast-enhanced MR angiography 1. Radiology 239(1):263–268PubMedCrossRef
124.
Coenegrachts KL, Hoogeveen RM, Vaninbroukx JA, et al. (2004) High-spatial-resolution 3D balanced turbo field-echo technique for MR angiography of the renal arteries: initial experience 1. Radiology 231(1):237–242PubMedCrossRef
125.
Artz NS, Sadowski EA, Wentland AL, et al. (2011) Arterial spin labeling MRI for assessment of perfusion in native and transplanted kidneys. Magn Reson Imaging 29(1):74–82PubMedPubMedCentralCrossRef
126.
Jin R, Lin B, Li D, Ai H (2014) Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications. Curr Opin Pharmacol 18:18–27PubMedCrossRef
127.
Bashir MR, Bhatti L, Marin D, Nelson RC (2015) Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging 41(4):884–898PubMedCrossRef
128.
Pai AB, Garba AO (2012) Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med 3:77PubMedPubMedCentral
129.
Wu Y, Briley-Saebo K, Xie J, et al. (2014) Inflammatory bowel disease: MR-and SPECT/CT-based macrophage imaging for monitoring and evaluating disease activity in experimental mouse model—pilot study. Radiology 271(2):400–407PubMedCrossRef
130.
Serkova NJ, Renner B, Larsen BA, et al. (2010) Renal Inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice 1. Radiology 255(2):517–526PubMedPubMedCentralCrossRef
131.
Neuwelt EA, Hamilton BE, Varallyay CG, et al. (2009) Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF) & quest. Kidney Int 75(5):465–474PubMedPubMedCentralCrossRef
132.
Ersoy H, Jacobs P, Kent CK, Prince MR (2004) Blood pool MR angiography of aortic stent-graft endoleak. Am J Roentgenol 182(5):1181–1186CrossRef
133.
Wilson SR, Burns PN (2010) Microbubble-enhanced US in body imaging: what role? 1. Radiology
134.
Piscaglia F, Bolondi L (2006) The safety of Sonovue® in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 32(9):1369–1375PubMedCrossRef
135.
Serra C, Menozzi G, Labate AMM, et al. (2007) Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn’s disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol 62(1):114–121PubMedCrossRef
136.
Tamai H, Takiguchi Y, Oka M, et al. (2005) Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. J Ultrasound Med 24(12):1635–1640PubMed
137.
Catalano O, Cusati B, Nunziata A, Siani A (2006) Active abdominal bleeding: contrast-enhanced sonography. Abdom Imaging 31(1):9–16PubMedCrossRef
138.
Christiansen JP, Lindner JR (2005) Molecular and cellular imaging with targeted contrast ultrasound. Proc IEEE 93(4):809–818CrossRef
Metadata
Title
Imaging patients with renal impairment
Authors
Mahan Mathur
Jeffrey C. Weinreb
Publication date
01-06-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 6/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0709-8

Other articles of this Issue 6/2016

Abdominal Radiology 6/2016 Go to the issue

OriginalPaper

Small (<4 cm) clear cell renal cell carcinoma: correlation between CT findings and histologic grade

Invited article

Renal applications of dual-energy CT

OriginalPaper

CT-guided paravertebral block for microwave ablation of kidney tumors: a new technique

Pictorial Essay

Inherited renal cystic diseases

Invited Article

CT urography in evaluation of urothelial tumors of the kidney

Pictorial Essay

MR urography in children and adolescents: techniques and clinical applications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits